Considering that 2,3-dioxygenase (IDO), an immunosuppressive agent, causes exhaustion and the increased formation of regulatory T cells (Tregs), synergizing with an IDO inhibitor can further improve the tumor immunotherapeutic potency and reverse T cell exhaustion [49]. This evidence concerns the gene IDO1 and neoplasm.